Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Sumoylation of the net inhibitory domain (NID) is stimulated by PIAS1 and has a negative effect on the transcriptional activity of Net

Oncogene volume 24, pages 820–828 (2005)Cite this article

Abstract

Net (Elk-3, Sap-2, Erp) and the related ternary complex factors Elk-1 and Sap-1 are effectors of multiple signalling pathways at the transcriptional level and play a key role in the dynamic regulation of gene expression. Net is distinct from Elk-1 and Sap-1, in that it is a strong repressor of transcription that is converted to an activator by the Ras/Erk signalling pathway. Two autonomous repression domains of Net, the NID and the CID, mediate repression. We have previously shown that the co-repressor CtBP is implicated in repression by the CID. In this report we show that repression by the NID involves a different pathway, sumoylation by Ubc9 and PIAS1. PIAS1 interacts with the NID in the two-hybrid assay and in vitro. Ubc9 and PIAS1 stimulate sumoylation in vivo of lysine 162 in the NID. Sumoylation of lysine 162 increases repression by Net and decreases the positive activity of Net. These results increase our understanding of how one of the ternary complex factors regulates transcription, and contribute to the understanding of how different domains of a transcription factor participate in the complexity of regulation of gene expression.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Buchwalter G, Gross C and Wasylyk B . (2004). Gene, 324, 1–14.

  • Chen C and Okayama H . (1987). Mol. Cell. Biol., 7, 2745–2752.

  • Chinnadurai G . (2002). Mol. Cell, 9, 213–224.

  • Chinnadurai G . (2003). BioEssays, 25, 9–12.

  • Criqui-Filipe P, Ducret C, Maira SM and Wasylyk B . (1999). EMBO J., 18, 3392–3403.

  • Giovane A, Pintzas A, Maira SM, Sobieszczuk P and Wasylyk B . (1994). Genes Dev., 8, 1502–1513.

  • Giovane A, Sobieszczuk P, Ayadi A, Maira SM and Wasylyk B . (1997). Mol. Cell. Biol., 17, 5667–5678.

  • Girdwood D, Bumpass D, Vaughan OA, Thain A, Anderson LA, Snowden AW, Garcia-Wilson E, Perkins ND and Hay RT . (2003). Mol. Cell, 11, 1043–1054.

  • Gong L, Kamitani T, Fujise K, Caskey LS and Yeh ET . (1997). J. Biol. Chem., 272, 28198–28201.

  • Hahn SL, Wasylyk B, Criqui-Filipe P and Criqui P . (1997). Oncogene, 15, 1489–1495.

  • Iniguez-Lluhi JA and Pearce D . (2000). Mol. Cell. Biol., 20, 6040–6050.

  • Janknecht R and Nordheim A . (1996a). Biochem. Biophys. Res. Commun., 228, 831–837.

  • Janknecht R and Nordheim A . (1996b). Oncogene, 12, 1961–1969.

  • Johnson ES . (2004). Annu. Rev. Biochem., 73, 355–382.

  • Kagey MH, Melhuish TA and Wotton D . (2003). Cell, 113, 127–137.

  • Kim J, Cantwell CA, Johnson PF, Pfarr CM and Williams SC . (2002). J. Biol. Chem., 277, 38037–38044.

  • Kotaja N, Aittomaki S, Silvennoinen O, Palvimo JJ and Janne OA . (2000). Mol. Endocrinol., 14, 1986–2000.

  • Kotaja N, Karvonen U, Janne OA and Palvimo JJ . (2002). Mol. Cell. Biol., 22, 5222–5234.

  • Le Drean Y, Mincheneau N, Le Goff P and Michel D . (2002). Endocrinology, 143, 3482–3489.

  • Lin X, Sun B, Liang M, Liang YY, Gast A, Hildebrand J, Brunicardi FC, Melchior F and Feng XH . (2003). Mol. Cell, 11, 1389–1396.

  • Long J, Matsuura I, He D, Wang G, Shuai K and Liu F . (2003). Proc. Natl. Acad. Sci. USA, 100, 9791–9796.

  • Maira SM, Wurtz JM and Wasylyk B . (1996). EMBO J., 15, 5849–5865.

  • Megidish T, Xu JH and Xu CW . (2002). J. Biol. Chem., 277, 8255–8259.

  • Melchior F, Schergaut M and Pichler A . (2003). Trends Biochem. Sci., 28, 612–618.

  • Muller S, Ledl A and Schmidt D . (2004). Oncogene, 23, 1998–2008.

  • Nishida T and Yasuda H . (2002). J. Biol. Chem., 277, 41311–41317.

  • Ross S, Best JL, Zon LI and Gill G . (2002). Mol. Cell, 10, 831–842.

  • Sachdev S, Bruhn L, Sieber H, Pichler A, Melchior F and Grosschedl R . (2001). Genes Dev., 15, 3088–3103.

  • Salinas S, Briancon-Marjollet A, Bossis G, Lopez MA, Piechaczyk M, Jariel-Encontre I, Debant A and Hipskind RA . (2004). J. Cell. Biol., 165, 767–773.

  • Sampson DA, Wang M and Matunis MJ . (2001). J. Biol. Chem., 276, 21664–21669.

  • Sapetschnig A, Rischitor G, Braun H, Doll A, Schergaut M, Melchior F and Suske G . (2002). EMBO J., 21, 5206–5215.

  • Schmidt D and Muller S . (2002). Proc. Natl. Acad. Sci. USA, 99, 2872–2877.

  • Schmidt D and Muller S . (2003). Cell. Mol. Life Sci., 60, 2561–2574.

  • Seeler JS and Dejean A . (2003). Nat. Rev. Mol. Cell. Biol., 4, 690–699.

  • Sharrocks AD . (2002). Biochem. Soc. Trans., 30, 1–9.

  • Shaw PE and Saxton J . (2003). Int. J. Biochem. Cell. Biol., 35, 1210–1226.

  • Subramanian L, Benson MD and Iniguez-Lluhi JA . (2003). J. Biol. Chem., 278, 9134–9141.

  • Tan JA, Hall SH, Hamil KG, Grossman G, Petrusz P and French FS . (2002). J. Biol. Chem., 277, 16993–17001.

  • Tussie-Luna MI, Bayarsaihan D, Seto E, Ruddle FH and Roy AL . (2002). Proc. Natl. Acad. Sci. USA, 99, 12807–12812.

  • Verger A, Perdomo J and Crossley M . (2003). EMBO Rep., 4, 137–142.

  • Yang SH, Bumpass DC, Perkins ND and Sharrocks AD . (2002). Mol. Cell. Biol., 22, 5036–5046.

  • Yang SH, Jaffray E, Hay RT and Sharrocks AD . (2003a). Mol. Cell, 12, 63–74.

  • Yang SH, Sharrocks AD and Whitmarsh AJ . (2003b). Gene, 320, 3–21.

Download references

Acknowledgements

We thank F Lehembre, A Dejean and RT Hay for the gift of recombinants, members of the Wasylyk laboratory for their friendly help, support and encouragement, and the IGBMC core services. We acknowledge for financial assistance: the Association pour la Recherche sur le Cancer, Aventis, the Ligue Nationale Française contre le Cancer (Equipe labellisée), the Ligue Régionale (Haut-Rhin) contre le Cancer, the Ligue Régionale (Bas-Rhin) contre le Cancer, the Centre National de la Recherche Scientifique, the Institut National de la Santé et de la Recherche Médicale, the Hôpital Universitaire de Strasbourg, and the European Union (FP5 project QLK6-2000-00159).

Author information

Authors and Affiliations

  1. Human Pathology, Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS/INSERM/ULP, 1 Rue Laurent Fries, BP 10142, 67404, Illkirch Cedex, France

    Christine Wasylyk, Paola Criqui-Filipe & Bohdan Wasylyk

Authors
  1. Christine Wasylyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paola Criqui-Filipe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bohdan Wasylyk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bohdan Wasylyk.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wasylyk, C., Criqui-Filipe, P. & Wasylyk, B. Sumoylation of the net inhibitory domain (NID) is stimulated by PIAS1 and has a negative effect on the transcriptional activity of Net. Oncogene 24, 820–828 (2005). https://doi.org/10.1038/sj.onc.1208226

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208226

Keywords

This article is cited by

Search

Advanced search

Quick links